ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Stomach Cancer
Cancer
Ovarian Cancer
Neoplasm Metastasis
Breast Cancer

Pancreatic Cancer trials near Warszawa, Mazowieckie, POL:

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours

activity in participants with advanced metastatic colorectal cancer, ovarian cancer, renal cancer or pancreatic c....

Enrolling
Metastatic Pancreatic Carcinoma
Advanced Pancreatic Carcinoma
Drug: OATD-02

Phase 1

Molecure

Warsaw, Masovian Voivodeship, Poland and 2 other locations

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid ...

Enrolling
Gastroesophageal Junction Cancer
Gastric Cancer
Drug: l-leucovorin
Drug: Gemcitabine

Phase 2

AstraZeneca
AstraZeneca

Warsaw, Poland and 51 other locations

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age...

Active, not recruiting
Breast Cancer
Biliary Cancer
Drug: Camizestrant
Drug: T- Dxd

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Warsaw, Poland and 67 other locations

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer...

Active, not recruiting
Breast Cancer
Colorectal Cancer (CRC)
Drug: Regorafenib
Drug: Capecitabine

Phase 2

Incyte
Incyte

Warsaw, Poland and 8 other locations

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor...

Active, not recruiting
Colorectal Cancer (CRC)
Non-Small Cell Lung Cancer (NSCLC)
Drug: RMC-6291

Phase 1

Revolution Medicines
Revolution Medicines

Warsaw, Poland and 63 other locations

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor...

Active, not recruiting
Breast Cancer
Papillary Thyroid Cancer
Drug: Entrectinib

Phase 2

Roche
Roche

Warsaw, Poland and 122 other locations

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02)

consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometri ...

Active, not recruiting
Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
Drug: Trastuzumab deruxtecan

Phase 2

AstraZeneca
AstraZeneca

Warsaw, Poland and 88 other locations

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic...

Enrolling
Solid Tumors
Drug: Investigator's choice of chemotherapy
Drug: Placebo

Phase 3

Incyte
Incyte

Warsaw, Poland and 227 other locations

Locations recently updated

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic...

Enrolling
Metastatic Pancreatic Ductal Adenocarcinoma
Cachexia
Drug: placebo
Drug: ponsegromab

Phase 2, Phase 3

Pfizer
Pfizer

Warsaw, Masovian Voivodeship, Poland and 223 other locations

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosph...

Active, not recruiting
Pancreatic Ductal Adenocarcinoma
Drug: Placebo
Drug: Nab-paclitaxel

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Warsaw, Poland and 268 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems